Sanofi (NASDAQ:SNY) (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines. Notable products developed or marketed by Sanofi include Dupixent (dupilumab), an immunology biologic for conditions such as atopic dermatitis and asthma developed in collaboration with Regeneron, and long‑acting insulin products in diabetes care. Through Sanofi Pasteur, the company produces vaccines for infectious diseases and maintains global vaccine manufacturing and distribution capabilities. Sanofi’s portfolio also encompasses over‑the‑counter and consumer healthcare items alongside its prescription medicines.
The current Sanofi group is the result of decades of industry consolidation and strategic acquisitions that brought together French and international pharmaceutical operations into a single global company. Sanofi invests heavily in research and development, focusing on biologics, vaccines, gene and cell therapies, and targeted small molecules to address unmet medical needs. Paul Hudson has served as chief executive officer since 2019, leading the company’s strategic priorities in innovation, portfolio optimization and global commercial execution.
